

HalioDx establishes US facilities in Richmond, Virginia and holds a CLIA certificate of registration for Immunoscore®

Marseille, France, and Richmond, VA, USA, January 8, 2019: HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, today announced that the company is expanding its North American operations with the inception of HalioDx Inc., located in Richmond, Virginia. The facility holds a CLIA certificate of registration for its flagship Immunoscore® assay and is now ready to receive and run samples. In parallel HalioDx has recruited a seasoned sales force and started the implementation of its reimbursement roadmap. Immunoscore® is a breakthrough immunohistochemistry assay powered by image analysis enabling to improve the management of localized colon cancer.

“After developing our international commercial network via distributors covering year-to-date 19 countries, we have now, with the opening of our Richmond lab, the capacity to offer directly Immunoscore® to US and Latin America patients.” said **Stephane Debono, EVP of the Diagnostics Business Unit at HalioDx and CEO of HalioDx Inc.**

“The North America market is critical for any innovative diagnostic company that has global ambition and opening our CLIA laboratory in Virginia plus building our own sales organization to serve directly US oncologists is a landmark for HalioDx. We expect also additional interest from Pharma as we are now able to run Immunoscore® closer to US clinical trials sites.” added **Vincent Fert President and CEO of HalioDx.**

HalioDx team is taking part in JP Morgan Healthcare conference January 7-10, in San Francisco, California. To schedule an appointment at the conference, please contact infos@haliodx.com.

About HalioDx

The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies. Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications.

HalioDx has an experienced team of more than 135 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites www.haliodx.com and www.immunoscore-colon.com and follow the company on Twitter [@HalioDx](https://twitter.com/HalioDx).

Contacts

HalioDx SAS

Vincent Fert

President and CEO

+ 33 (0)4 91 29 30 90

vincent.fert@haliodx.com

ATCG Press

Marie Puvieux (France)

Mob: +33 (0)6 10 54 36 72

Céline Voisin (ROW)

Mob: +33 (0)6 62 12 53 39

haliodx@atcg-partners.com

[Twitter: twitter.com/haliodx](https://twitter.com/haliodx)